Researchers at the University of California, Berkeley have identified a molecular compound, 5-tetradecyloxy-2-furoic acid (TOFA), which enhances energy expenditure to treat obesity and diabetes, contrasting with GLP-1 medications that primarily reduce caloric intake. Published on August 21 in Science Advances, the study demonstrates that TOFA interferes with lipid production while activating genes that promote fat utilization for energy. In mouse experiments, TOFA improved insulin sensitivity, glucose control, and reduced triglyceride levels, leading to fat loss without significant muscle mass reduction.
TOFA, initially discovered in the 1970s as an ACC inhibitor, uniquely activates PPARα and PPARδ receptors, which enhance fat metabolism and energy expenditure. Unlike other ACC inhibitors that may increase triglycerides and cardiovascular risk, TOFA did not exhibit this side effect, potentially due to its dual action on lipid synthesis and energy metabolism. The researchers also found that combining TOFA with GLP-1 drugs, such as semaglutide and tirzepatide, resulted in greater improvements in body weight, glucose control, insulin levels, and triglycerides compared to either treatment alone, suggesting a complementary rather than replacement role. However, the study emphasizes that TOFA’s effects have only been observed in animal models, and its safety and efficacy in humans remain to be determined. Source